12:00 AM
Sep 28, 2009
 |  BC Week In Review  |  Company News  |  Deals

Qiagen, DxS, Idaho Technology, Roche deal

Qiagen acquired DxS in a deal valued at $95 million in cash, plus up to $35 million if commercial and other milestones are met. Qiagen gains DxS' marketed portfolio of seven real-time PCR tests to predict patient response to cancer treatments. Qiagen said the assays...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >